Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells

Cellular Oncology

Volumn 37, Issue 5, 2014, Pages 377-386

  Ahn, Sun Hee ^a   Jeong, Eun Hui ^a   Lee, Tae Gul ^a   Kim, Seo Yun ^a   Kim, Hye Ryoun ^a   Kim, Cheol Hyeon ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Apoptosis; Caspase 8; Epidermal growth factor receptor; Gefitinib; Non small cell lung cancer; p27

Indexed keywords

CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN; PROTEIN P41; PROTEIN P43; UNCLASSIFIED DRUG; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; CYTOPLASMIC TRANSLOCATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; GENE DELETION; GENE MUTATION; HCC827 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; ONCOGENE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REDUCTION; ANTAGONISTS AND INHIBITORS; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 8; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MICROSCOPY, CONFOCAL; MUTATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84907726857     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0198-0     Document Type: Article

References (38)

1. F. Ciardiello, G. Tortora, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958-2970 (2001)
2. W. Pao, V.A. Miller, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568 (2005)
3. A. Koren, H. Motaln, T. Cufer, Lung cancer stem cells: a biological and clinical perspective. Cell Oncol 36, 265-275 (2013)
4. N. Peled, M.W. Wynes, N. Ikeda, T. Ohira, K. Yoshida, J. Qian, M. Ilouze, R. Brenner, Y. Kato, C. Mascaux, F.R. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol 36, 277-288 (2013)
5. A.E. Wakeling, S.P. Guy, J.R. Woodburn, S.E. Ashton, B.J. Curry, A.J. Barker, K.H. Gibson, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749-5754 (2002)
6. V.D. Cataldo, D.L. Gibbons, R. Pérez-Soler, A. Quintás-Cardama, Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 364, 947-955 (2011)
7. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004)
8. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004)
9. H. Linardou, I.J. Dahabreh, D. Bafaloukos, P. Kosmidis, S. Murray, Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 6, 352-366 (2009)
10. S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B.E. Johnson, P.A. Jänne, Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64, 7241-7244 (2004)
11. S.V. Sharma, P. Gajowniczek, I.P. Way, D.Y. Lee, J. Jiang, Y. Yuza, M. Classon, D.A. Haber, J. Settleman, A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-435 (2006)
12. G.C. Chang, S.L. Hsu, J.R. Tsai, F.P. Liang, S.Y. Lin, G.T. Sheu, C.Y. Chen, Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem. Pharmacol. 68, 1453-1464 (2004)
13. G.K. Schwartz, M.A. Shah, Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23, 9408-9421 (2005)
14. M. Boehm, T. Yoshimoto, M.F. Crook, S. Nallamshetty, A. True, G.J. Nabel, E.G. Nabel, A growth factor-dependent nuclear kinase phosphorylates p27 (Kip1) and regulates cell cycle progression. EMBO J. 21, 3390-3401 (2002)
15. S. Shintani, C. Li, M. Mihara, J. Yano, N. Terakado, K. Nakashiro, H. Hamakawa, Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol. 40, 43-51 (2004)
16. O. Coqueret, New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13, 65-70 (2003)
17. I.M. Chu, L. Hengst, J.M. Slingerland, The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8, 253-267 (2008)
18. G. Rodier, A. Montagnoli, L. Di Marcotullio, P. Coulombe, G.F. Draetta, M. Pagano, S. Meloche, p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 20, 6672-6682 (2001)
19. A. Besson, M. Gurian-West, X. Chen, K.S. Kelly-Spratt, C.J. Kemp, J.M. Roberts, A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization and tumor suppression. Genes Dev. 20, 47-64 (2006)
20. N.A. Thornberry, Y. Lazebnik, Caspases: enemies within. Science 281, 1312-1316 (1998)
21. N. Shinoura, T. Furitsu, A. Asai, T. Kirino, H. Hamada, Co-transfection of p27Kip1 strongly augments Fas ligand- and caspase-8-mediated apoptosis in U-373MG glioma cells. Anticancer Res. 21, 3261-3268 (2001)
22. X.B. Yan, D.S. Yang, X. Gao, J. Feng, Z.L. Shi, Z. Ye, Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol. Int. 31, 1136-1143 (2007)
23. J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M.K. Connor, K. Han, J.H. Lee, S. Ciarallo, C. Catzavelos, R. Beniston, E. Franssen, J.M. Slingerland, PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8, 1153-1160 (2002)
24. I. Shin, F.M. Yakes, F. Rojo, N.Y. Shin, A.V. Bakin, J. Baselga, C.L. Arteaga, PKB/Akt mediates cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8, 1145-1152 (2002)
25. G. Viglietto, M.L. Motti, P. Bruni, R.M. Melillo, A. D'Alessio, D. Califano, F. Vinci, G. Chiappetta, P. Tsichlis, A. Bellacosa, A. Fusco, M. Santoro, Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27 (Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8, 1136-1144 (2002)
26. J. Philipp-Staheli, S.R. Payne, C.J. Kemp, p27 (Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. 264, 148-168 (2001)
27. C. Craig, R. Wersto, M. Kim, E. Ohri, Z. Li, D. Katayose, S.J. Lee, J. Trepel, K. Cowan, P. Seth, A recombinant adenovirus p27kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14, 2283-2289 (1997)
28. Y. Katayose, M. Kim, A.N. Rakkar, Z. Li, K.H. Cowan, P. Seth, Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 57, 5441-5445 (1997)
29. A.L. Katner, Q.B. Hoang, P. Gootam, E. Jaruga, Q. Ma, J. Gnarra, W. Rayford, Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27Kip1. Prostate 53, 77-87 (2002)
30. K. Supriatno, M.O. Harada, T. Hoque, H. Bando, M. Yoshida, Sato, overexpression of p27 (Kip1) induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol. 38, 730-736 (2002)
31. Q. Zhang, L. Tian, A. Mansouri, A.L. Korapati, T.J. Johnson, F.X. Claret, Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Lett. 579, 3932-3940 (2005)
32. I. Naruse, H. Hoshino, K. Dobashi, K. Minato, R. Saito, M. Mori, Over-expression of p27kip1 induces growth lung cancer cell lines. Int. J. Cancer 88, 377-383 (2000)
33. M. Ohtani, H. Isozaki, K. Fujii, E. Nomura, M. Niki, H. Mabuchi, K. Nishiguchi, M. Toyoda, T. Ishibashi, N. Tanigawa, Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer 85, 1711-1718 (1999)
34. S.P. Singh, J. Lipman, H. Goldman, F.H. Ellis Jr., L. Aizenman, M.G. Cangi, S. Signoretti, D.S. Chiaur, M. Pagano, M. Loda, Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58, 1730-1735 (1998)
35. A. Sgambato, C. Ratto, B. Faraglia, M. Merico, R. Ardito, G. Schinzari, G. Romano, A.R. Cittadini, Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27 (Kip1) in human colon cancer. Mol. Carcinog. 26, 172-179 (1999)
36. V. Masciullo, A. Sgambato, C. Pacilio, B. Pucci, G. Ferrandina, J. Palazzo, A. Carbone, A. Cittadini, S. Mancuso, G. Scambia, A. Giordano, Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 59, 3790-1794 (1999)
37. V. Masciullo, T. Susini, A. Zamparelli, A. Bovicelli, C. Minimo, D. Massi, G. Taddei, N. Maggiano, P. De Iaco, M. Ceccaroni, L. Bovicelli, G. Amunni, S. Mancuso, G. Scambia, A. Giordano, Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 (Kip1) in estrogen-related endometrial adenocarcinomas. Clin. Cancer Res. 9, 5332-5338 (2003)
38. Y.H. Ling, T. Li, Z. Yuan, M. Haigentz Jr., T.K. Weber, R. Perez-Soler, Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol. Pharmacol. 72, 248-258 (2007)